论文部分内容阅读
为了解克氏原螯虾产ESBLs大肠杆菌的耐药流行情况,采集来自山东、江苏、浙江、湖北和辽宁五省共计198份活体克氏原螯虾肠道样品,采用头孢噻肟抗性选择性培养基培养、PCR方法和BD PhoenixTM-100全自动微生物鉴定/药敏系统筛选、鉴定产ESBLs大肠杆菌并检测其药物敏感性。结果显示,从198份克氏原螯虾样品中共分离获得107株产ESBLs大肠杆菌,分离率为54.0%。所有分离菌株对青霉素类、一代头孢和部分三代头孢菌素均耐药;对四环素类、氟喹诺酮类、氯霉素类和磺胺类药物的耐药率均在60%以上(>65株);对氨基糖苷类药物耐药率较低;多重耐药(R≥3类)菌株所占比例为86.7%(96/107),且以5类(30%,31/107)和6类耐药(28%,30/107)为主。通过试验初步获得了克氏原螯虾产ESBLs大肠杆菌耐药水平的基础数据,为克氏原螯虾细菌耐药性防控和水产品公共卫生监测奠定基础。
In order to understand the prevalence of ESBLs-producing Escherichia coli in Procambarus clarkii, a total of 198 intestinal samples were collected from five provinces of Shandong, Jiangsu, Zhejiang, Hubei and Liaoning provinces and selected by cefotaxime resistant selective culture Base culture, PCR method and BD PhoenixTM-100 automatic microbial identification / drug susceptibility screening, ESBLs-producing Escherichia coli was identified and tested for drug sensitivity. The results showed that 107 strains of ESBLs-producing Escherichia coli were isolated from 198 samples of Procambarus clarkia, the isolation rate was 54.0%. All isolates were resistant to penicillins, cephalosporins and some third generation cephalosporins. The resistance rates to tetracyclines, fluoroquinolones, chloramphenicol and sulfonamides were over 60% (> 65 strains). The rate of resistance to aminoglycosides was low. The percentage of multi-drug resistant strains (R≥3) was 86.7% (96/107), and the rate of resistance to aminoglycosides was 5 (30%, 31/107) (28%, 30/107). The preliminary data of the ESBLs-producing Escherichia coli resistance of Procambarus clarkii was obtained through experiments, which laid the foundation for the prevention and control of the drug resistance and the public health monitoring of aquatic products.